Clinical Trials Browser

Has announcements × Bronchiolitis Obliterans Syndrome × Clear all

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03790332 2025-10-21

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Phase 1/2 Completed

59 enrolled 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03640481 2024-12-12

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Phase 2 Terminated

159 enrolled 25 charts 1 FDA

Bronchiolitis Obliterans Syndrome

NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase 3 Completed

536 enrolled 24 charts 1 FDA

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01844765 2021-04-22

DIALOG

Phase 2 Completed

59 enrolled 33 charts 1 FDA

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myeloproliferative Disorders, Neoplastic Processes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02195869 2019-07-11

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Phase 1/2 Completed

45 enrolled 13 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Clinical Trials

AGAVE-201

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

DIALOG

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease